(NRSN) Neurosense Therapeutics - Ratings and Ratios

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company dedicated to addressing neurodegenerative diseases through innovative therapeutic solutions. The companys primary focus is on developing treatments for amyotrophic lateral sclerosis (ALS), Alzheimers disease, and Parkinsons disease. Its lead product, PrimeC, is an extended-release oral formulation combining ciprofloxacin and celecoxib. PrimeC is currently in Phase 2b/3 clinical trials for ALS and has completed Phase 2 trials for Alzheimers disease, with preclinical investigations underway for Parkinsons disease. NeuroSenses preclinical pipeline also includes StabiliC, a compound targeting Parkinsons disease, and CogniC, aimed at treating Alzheimers disease. Founded in 2017, the company is headquartered in Herzliya, Israel, and has established a robust research and development framework to advance its neurological disorder treatments. For more information, visit https://www.neurosense-tx.com.

Ticker Symbol: NRSN (NASDAQ) represents NeuroSense Therapeutics Ltd., a biotechnology company based in Israel. The stock is classified as common equity in the biotechnology sector.

From a technical standpoint, NRSN has shown a 20-day average volume of 113,558 shares, with a last price of $1.13. The stocks Simple Moving Averages (SMA) indicate a 20-day SMA of $1.12, a 50-day SMA of $1.13, and a 200-day SMA of $1.07. The Average True Range (ATR) is $0.08, reflecting low volatility in recent trading activity.

Fundamentally, NeuroSense Therapeutics has a market capitalization of $25.73 million. The companys price-to-book (P/B) ratio is 4.15, indicating a premium valuation relative to its book value. The return on equity (RoE) stands at 403.09%, suggesting significant leverage or operational efficiency. However, the lack of positive earnings is reflected in the zero P/E and forward P/E ratios.

3-Month Forecast: Based on current price trends and volatility, NRSN is expected to trade within a narrow range of $1.00 to $1.25. Given the companys clinical trial pipeline and market positioning, any positive trial results could drive upward momentum, while negative outcomes may lead to a retest of support levels near $1.00. The stocks low average volume and tight ATR suggest limited near-term volatility unless catalyzed by material news.